TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 1827311
Drug: Spiroplatin at
Normalized name: rose bengal AT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spiroplatin at 40 mg/m2 (MTD for good-risk patients)
Study: 1827311
Drug: Spiroplatin (dose-dependent)
Normalized name: Picoplatin
DrugBank: Picoplatin (DB04874)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spiroplatin (dose-dependent)
Study: 7479625
Drug: 2‐mg nicotine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2‐mg nicotine gum
Study: 11082826
Drug: 4‐mg nicotine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4‐mg nicotine gum
Study: 25195060
Drug: Betamethasone (8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Betamethasone (8 mg intravenously before surgery)
Study: 9644112
Drug: PGE1 infusion
Normalized name: PGE1
DrugBank: Alprostadil (DB00770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: PGE1 infusion (30 micrograms/h for 2-6 h)
Study: 7840523
Drug: Tamoxifen alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tamoxifen alone (loading dose of 160 mg on the first day)
Study: 31920008
Drug: Chemotherapy in
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy in EGFR-negative tumors
Study: 17698986
Drug: Lipid/heparin-somatostatin-insulin-glucagon clamps
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lipid/heparin-somatostatin-insulin-glucagon clamps
Study: 2665305
Drug: Routine treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine treatment of ulcers
Study: 989965
Drug: High molecular
Normalized name: dextran, high molecular weight
Approvals — FDA: no, EMA: no, PMDA: no
Description: High molecular weight sodium heparin (mean m.w. 22,000)
Study: 24192751
Drug: 750 mg
Normalized name: bran 750 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 750 mg telaprevir (TVR) at 8 h intervals
Study: 24192751
Drug: 750 mg
Normalized name: bran 750 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 750 mg telaprevir (TVR) at 12 h intervals
Study: 19081706
Drug: Human growth
Normalized name: Human growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Human growth hormone (0.1 mg . kg(‐1) . d(‐1))
Study: 10787112
Drug: Subcutaneous placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous placebo
Study: 17225037
Drug: Therapy by
Normalized name: By Ache
Approvals — FDA: no, EMA: no, PMDA: no
Description: Therapy by therapists
Study: 17225037
Drug: Daily therapy
Normalized name: Konsyl Daily Therapy Fiber Laxative 625mg Caplet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily therapy by more than one therapist
Study: 17225037
Drug: Upper-limb therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Upper-limb therapy
Study: 17225037
Drug: Presence of
Normalized name: Dna Plasmid Expressing Diphtheria Toxin Triggered By The Presence Of Oncofetal Gene H19
DrugBank: Inodiftagene vixteplasmid (DB16017)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Presence of family members during therapy
Study: 12482192
Drug: 4 doses
Normalized name: parathyroid hormone 25 MCG/Dose Cartridge, 14 Doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 doses of the HiB vaccine (PPR‐D, Connaught) starting at 3 months of life
Study: 12482192
Drug: 0 doses
Normalized name: mometasone furoate 220 mcg/actuation (30 doses) INHALATION AEROSOL POWDER, BREATH ACTIVATED (EA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0 doses of the HiB vaccine (control group)
Study: 9935122
Drug: Dexamethasone 9
Normalized name: DEXAMETHASONE 9% INTRAOCULAR SUSP KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone 9 mg daily for 15 days, followed by a stepwise decrease in dosage, plus 300 IU of hMG daily for 10 days
Study: 9935122
Drug: Placebo, plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo, plus 300 IU of hMG daily for 10 days
Study: 7769049
Drug: No treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: No treatment (control group, n = 11)
Study: 2180233
Drug: Cold-adapted influenza
Normalized name: INFLUENZA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cold-adapted influenza B live attenuated intranasal vaccine
Study: 31757354
Drug: Cocaine users
Normalized name: Cocaine
DrugBank: Cocaine (DB00907)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cocaine users with negative drug screen
Study: 19285833
Drug: Diet containing
Normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diet containing 25 g of cellulose
Study: 11463772
Drug: Bromocriptine (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bromocriptine (2.5 mg) alone
Study: 7797824
Drug: pantoprazole (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: pantoprazole (40 mg once daily)
Study: 7797824
Drug: ranitidine (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: ranitidine (150 mg b.i.d.)
Study: 2121268
Drug: 20 g
Normalized name: PEG-20 glyceryl oleate
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 g alcohol in concentrations of 75, 180 and 300 ml/l water; RMR measured for 60 min; thermic effect measured for 90 min.
Study: 2121268
Drug: 20 g
Normalized name: PEG-20 glyceryl oleate
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 g alcohol in a 180 ml/l solution plus a meal of food (2 MJ); DIT measured for 240 min.
Study: 385764
Drug: RIT 4025
Normalized name: measles virus vaccine live, attenuated Schwarz strain / mumps virus vaccine live, RIT-4385 strain / rubella virus vaccine live (Wistar RA 27-3 strain) Injection [Priorix]
Approvals — FDA: no, EMA: no, PMDA: no
Description: RIT 4025 live recombinant strain (10(7.2) EID 50/dose, one or two doses at 2 weeks' interval)
Study: 385764
Drug: Inactivated vaccine
Normalized name: diphtheria toxoid vaccine, inactivated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inactivated vaccine (360 i.u. A/Port Chalmers/1/73 (H3N2), 300 i.u. A/Scotland/840/74 (H3N2), 300 i.u. B/Hong Kong/8/73, 300 i.u./dose, one injection)
Study: 30561704
Drug: Intravenous acetaminophen
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous acetaminophen (1 g every eight hours, three doses)
Study: 30561704
Drug: Oral acetaminophen
Normalized name: acetaminophen Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral acetaminophen (1 g every eight hours, three doses)
Study: 30561704
Drug: No acetaminophen
Approvals — FDA: no, EMA: no, PMDA: no
Description: No acetaminophen
Study: 20139856
Drug: IFX/HC (Hydrocortisone
Approvals — FDA: no, EMA: no, PMDA: no
Description: IFX/HC (Hydrocortisone 250 mg intravenously)
Study: 20139856
Drug: IFX/AZA (Azathioprine
Approvals — FDA: no, EMA: no, PMDA: no
Description: IFX/AZA (Azathioprine 2-2.5 mg/kg/day)
Study: 11134099
Drug: Transdermal testosterone
Normalized name: testosterone Transdermal System
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal testosterone gel 50 mg/day
Study: 11422108
Drug: Transdermal testosterone
Normalized name: testosterone Transdermal System
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal testosterone patches (5 mg T/day)
Study: 9231954
Drug: Weekly phone
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Weekly phone calls to uncover problems and encourage use
Study: 2902681
Drug: 150 mg
Normalized name: pectin 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 mg zaltidine once daily for 4 weeks
Study: 28645949
Drug: 4.5 g/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4.5 g/day S. maxima intake
Study: 11509081
Drug: Entacapone (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Entacapone (200 mg with each of 2-10 daily levodopa doses)
Study: 7607776
Drug: Group-administered questionnaire
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group-administered questionnaire in the workplace
Study: 8480685
Drug: Zinc supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zinc supplementation (10 mg Zn/d, n = 65)
Study: 30097067
Drug: Citrulline malate
Normalized name: CITRULLINE MALATE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Citrulline malate (CM) 8 g (1.11:1 ratio)
Study: 26834211
Drug: Secukinumab IV
Normalized name: Secukinumab
DrugBank: Secukinumab (DB09029)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Secukinumab IV loading 10 mg/kg at baseline, Weeks 2 and 4, then SC 150 mg every 4 weeks (n = 88)
Study: 26834211
Drug: Secukinumab SC
Normalized name: Secukinumab
DrugBank: Secukinumab (DB09029)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Secukinumab SC loading 150 mg once weekly for 5 weeks, then every 4 weeks (n = 89)
Study: 24145221
Drug: Ziprasidone augmentation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ziprasidone augmentation of clozapine
Study: 18318568
Drug: Zoledronic acid
Normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Zoledronic acid therapy
Study: 11180026
Drug: Moxifloxacin 800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moxifloxacin 800 mg
Study: 20406223
Drug: Levofloxacin 1000
Normalized name: Levofloxacine
DrugBank: Levofloxacin (DB01137)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Levofloxacin 1000 mg
Study: 9310011
Drug: Ciprofloxacin 1500
Normalized name: Ciprofloxacin
DrugBank: Ciprofloxacin (DB00537)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ciprofloxacin 1500 mg
Study: 10898688
Drug: Intravenous magnesium
Normalized name: immunoglobulins, intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous magnesium sulfate (MgSO4) at doses of 1, 2, and 3 g
Study: 3658552
Drug: Intravenous magnesium
Normalized name: immunoglobulins, intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous magnesium sulfate (MgSO4)
Study: 1811970
Drug: Intermaxillary wiring
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermaxillary wiring with subsequent functional therapy and/or functional appliances
Study: 6347747
Drug: 15 mg
Normalized name: papain 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mg of quazepam
Study: 29098286
Drug: Topical medications
Normalized name: Procto-Med Topical Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical medications
Study: 24727262
Drug: Interaction between
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Interaction between treatment and baseline MD
Study: 23043563
Drug: PSA-based screening
Approvals — FDA: no, EMA: no, PMDA: no
Description: PSA-based screening with a threshold of ≥ 3.0 ng/mL
Study: 17518105
Drug: Form priming
Normalized name: epinephrine
DrugBank: Epinephrine (DB00668)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Form priming with related primes and targets (e.g., lou3 'hug'‐‐lou2 'hall')
Study: 11785593
Drug: Alfentanil (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alfentanil (0.5 mg IV)
Study: 1632533
Drug: Morphine (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine (5 mg IV)
Study: 7921469
Drug: PC20FEV1 <
Approvals — FDA: no, EMA: no, PMDA: no
Description: PC20FEV1 < or = 25 mg/ml (AHR25)
Study: 30476361
Drug: Samidorphan (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Samidorphan (10 mg)
Study: 30476361
Drug: Samidorphan (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Samidorphan (30 mg)
Study: 28340145
Drug: Oxycodone (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxycodone (40 mg)
Study: 9513799
Drug: Pentazocine (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pentazocine (30 mg)
Study: 8539322
Drug: Naltrexone (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naltrexone (100 mg)
Study: 28117843
Drug: Lithium (serum
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lithium (serum level 0.6 mmol l-1, n=20)
Study: 28117843
Drug: Quetiapine (flexibly
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quetiapine (flexibly dosed up to 800 mg per day, n=19)
Study: 23230135
Drug: Tamoxifen treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tamoxifen treatment in pre- and postmenopausal women
Study: 18054209
Drug: Paroxetine plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paroxetine plus pindolol (2.5 mg t.i.d.)
Study: 14621239
Drug: Control solutions
Normalized name: Accu-Chek Comfort Curve Control Solutions
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Control solutions (tap water, Carbopol, Carbopol-urea)
Study: 10811092
Drug: cyclosporin A
Normalized name: Cyclosporin A
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: cyclosporin A ophthalmic emulsion 0.05%
Study: 10811092
Drug: cyclosporin A
Normalized name: Cyclosporin A
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: cyclosporin A ophthalmic emulsion 0.1%
Study: 3932051
Drug: Cimetidine 300
Normalized name: cimetidine 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cimetidine 300 mg, q.i.d.
Study: 20008701
Drug: Patch +
Normalized name: Patch
DrugBank: Lavender oil (DB14566)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patch + lozenge
Study: 20008701
Drug: Bupropion SR
Normalized name: Bupropion Hydrochloride 100 MG Oral Tablet, Extended Release, 12 HR [BUPROPION SR]
DrugBank: Bupropion (DB01156)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bupropion SR + lozenge
Study: 14564941
Drug: Daily foodlet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily foodlet containing multiple micronutrients
Study: 14564941
Drug: Daily placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily placebo foodlet containing no micronutrients
Study: 14564941
Drug: Weekly foodlet
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Weekly foodlet containing multiple micronutrients (twice the dose of the daily foodlet) and placebo foodlets on other days
Study: 14564941
Drug: Daily foodlet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily foodlet containing only 10 mg of elemental iron
Study: 4005103
Drug: Ciclazindol hydrochloride
Normalized name: Chlorpromazine Hydrochloride
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ciclazindol hydrochloride (50 mg twice daily)
Study: 31144979
Drug: Diet with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diet with 0.6 g protein/kg body weight
Study: 31144979
Drug: Diet with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diet with 1 g protein/kg body weight
Study: 29566934
Drug: Once-daily 7.5mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once-daily 7.5mg tolvaptan
Study: 26272586
Drug: Low-fat meal
Normalized name: bone meal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-fat meal (500 mg ceritinib)
Study: 26272586
Drug: High-fat meal
Normalized name: bone meal
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-fat meal (500 mg ceritinib)
Study: 24819761
Drug: 10% LF
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10% LF ointment
Study: 24819761
Drug: 20% LF
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20% LF ointment
Study: 15765988
Drug: 6.5 mg
Normalized name: menthol 6.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6.5 mg dose of bupivacaine with 20 microg of fentanyl
Study: 15374060
Drug: Carvedilol (6.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carvedilol (6.25 mg twice daily for the first week, increased to 12.5 mg during weeks 2-4, and to 25 mg from weeks 5-12)
Study: 11127843
Drug: Intravenous dihydralazine
Normalized name: dihydralazine
DrugBank: Dihydralazine (DB12945)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous dihydralazine
Study: 30753625
Drug: Lipid-based nutrient
Normalized name: guggul lipids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lipid-based nutrient supplements (LNSs) during pregnancy and postpartum plus LNSs for infants from 6 to 18 months
Study: 30753625
Drug: Non-LNS group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-LNS group (iron and folic acid during pregnancy and 200 mg Ca for 6 months postpartum; multiple micronutrients during pregnancy and postpartum)
Study: 27016157
Drug: Definitive abutment
Normalized name: Augmented Topical Cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Definitive abutment placed at the time of implant placement
Study: 23907700
Drug: Simeprevir (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simeprevir (75 or 150 mg QD) with Pegylated interferon and ribavirin
Study: 18987053
Drug: morphine 1
Normalized name: morphine 10 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: morphine 1 mg ml(‐1) plus dexmedetomidine 5 microg ml(‐1) (Group D)
Study: 18987053
Drug: morphine 1
Normalized name: morphine 10 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: morphine 1 mg ml(‐1) alone (Group M)
Study: 31250182
Drug: Rehabilitation program
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rehabilitation program (8-week, bi-weekly education and exercise program)
Study: 22093849
Drug: Methylprednisolone 1000
Normalized name: methylprednisolone 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylprednisolone 1000 mg/d for 3 days
Study: 14996518
Drug: Glimepiride (initially
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glimepiride (initially 2 mg once daily, increased by 1 mg every 2 weeks until FPG <6.7 mmol/L, maintained for 24 weeks)
Study: 14996518
Drug: Oral glucose
Normalized name: glucose Oral Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral glucose tolerance tests (OGTTs) conducted in the control group
Study: 7240597
Drug: Potassium metabisulfite
Normalized name: Potassium Metabisulfite
DrugBank: Potassium metabisulfite (DB15841)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Potassium metabisulfite (K2S2O5) oral challenges
Study: 20214065
Drug: Acupuncture combined
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture combined with oral administration of Propranolol
Study: 20214065
Drug: Oral administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral administration of Propranolol only
Study: 16239762
Drug: Amantadine 200
Normalized name: amantadine 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amantadine 200 mg twice daily
Study: 11851956
Drug: Mass drug
Normalized name: Xenon, isotope of mass 129
DrugBank: Xenon Xe-129 (DB17386)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mass drug administration (MDA) of diethylcarbamazine (DEC) plus ivermectin (IVR) with vector control
Study: 28398692
Drug: 7 days
Normalized name: ZINGIBER OFFICINALE (GINGER) ROOT OIL 0.006 mg in 30 mg TOPICAL LIQUID [JAYSUING 7 Days Nail Fungus Treatment]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7 days intravenous antibiotics
Study: 28398692
Drug: 10 days
Normalized name: AlleRx 10-day Dose Pack
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 days intravenous antibiotics
Study: 24513025
Drug: Atomoxetine (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atomoxetine (60 mg)
Study: 14722176
Drug: Fentanyl 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fentanyl 0.5 micro g kg(‐1)
Study: 14722176
Drug: Fentanyl 1
Normalized name: fentanyl 1.2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fentanyl 1 micro g kg(‐1)
Study: 14722176
Drug: Fentanyl 2
Normalized name: fentanyl 2.5 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fentanyl 2 micro g kg(‐1)
Study: 14722176
Drug: Fentanyl (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fentanyl (0.5 to 1 micro g kg(‐1))
Study: 11712623
Drug: Netamiftide (18
Approvals — FDA: no, EMA: no, PMDA: no
Description: Netamiftide (18 mg/patient per day) for 10 days
Study: 11712623
Drug: Netamiftide (18
Approvals — FDA: no, EMA: no, PMDA: no
Description: Netamiftide (18 mg/patient per day) for 5 days followed by 5 days of placebo
Study: 9042130
Drug: Pill form
Normalized name: Methio-Form Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pill form of cholestyramine (8 gm/day)
Study: 2835964
Drug: E +
Normalized name: Perle +
Approvals — FDA: no, EMA: no, PMDA: no
Description: E + H 25 (Enalapril + Hydrochlorothiazide 25 mg/day)
Study: 26967547
Drug: 15-minute 1-mA
Normalized name: TAGETES MINUTA FLOWER OIL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15-minute 1-mA subsensory (sham) treatment
Study: 9052356
Drug: Intranasal cocaine
Normalized name: Cocaine
DrugBank: Cocaine (DB00907)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal cocaine
Study: 8442748
Drug: Behaviour Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Behaviour Therapy
Study: 6626112
Drug: Placebo Medication
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo Medication
Study: 29968686
Drug: Laughter therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Laughter therapy program (12 sessions for 6 weeks)
Study: 21804338
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no laughter therapy)
Study: 25493968
Drug: Protocolized sedation
Normalized name: Tavist Non-Sedating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Protocolized sedation plus daily sedation interruption
Study: 15565494
Drug: S-L-tryptophan
Normalized name: L-TRYPTOPHAN
DrugBank: Tryptophan (DB00150)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: S-L-tryptophan
Study: 8306050
Drug: Inhaled beclomethasone
Normalized name: beclomethasone Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled beclomethasone (500 micrograms four times daily) for 1 month
Study: 2656624
Drug: Cefmetazole (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefmetazole (1 g doses administered intravenously 30-90 min before incision, followed by additional doses at 8 and 16 hours later)
Study: 30406725
Drug: Regular intermittent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regular intermittent epidural injection at L3-4
Study: 30406725
Drug: Regular intermittent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regular intermittent epidural injection at L4-5
Study: 10403264
Drug: Tramadol 200
Normalized name: TRAMADOL 200MG (RYZOLT) SA TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tramadol 200 mg/day
Study: 28881493
Drug: Tramadol 400
Normalized name: tramadol hydrochloride 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tramadol 400 mg/day
Study: 28881493
Drug: Tramadol (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tramadol (all doses)
Study: 24725475
Drug: PMMA-collagen injections
Approvals — FDA: no, EMA: no, PMDA: no
Description: PMMA-collagen injections
Study: 19201295
Drug: 1,25(OH)(2)D(3) treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1,25(OH)(2)D(3) treatment for 3 weeks
Study: 17465090
Drug: New drugs
Approvals — FDA: no, EMA: no, PMDA: no
Description: New drugs for the treatment of type 2 diabetes
Study: 15382007
Drug: 0.125% bupivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.125% bupivacaine with 2 micro g/ml fentanyl
Study: 15382007
Drug: 0.125% bupivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.125% bupivacaine with 1.5 micro g/ml clonidine
Study: 2397544
Drug: Routine treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine treatments such as oryzanol, vitamin B1 and B6
Study: 626430
Drug: Epidural placement
Normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural placement of saline solution